Transmission Dynamics of Carbapenemase Genes in Clinical CRE
2026-05-05
This study provides an in-depth molecular and epidemiological analysis of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) across eight teaching hospitals in Guangdong, China. By elucidating gene localization, transferability, and resistance profiles during the COVID-19 pandemic, the research highlights critical challenges for antibacterial research and infection control strategies.
Risedronate Sodium: Advanced Nanodelivery and Translational
2026-05-04
Explore the multifaceted applications of Risedronate Sodium, a potent FPP synthase inhibitor, with a focus on nano-enabled delivery and translational research in bone metabolism and pulmonary disease. This article offers unique insights and evidence-based guidance beyond standard protocols.
Chlorogenic Acid–Metal Supramolecules: Enhanced Anti-inflamm
2026-05-04
This study demonstrates that supramolecular assemblies of chlorogenic acids with iron and copper ions exhibit significantly improved anti-inflammatory efficacy compared to the parent molecules. By inhibiting the NF-κB pathway and suppressing key inflammatory mediators in macrophages, these metal-based complexes represent a promising new class of anti-inflammatory agents with mechanistic clarity.
Puerarin Regulates Gut Microbiota and Thermogenesis in T2D M
2026-05-03
This study demonstrates that puerarin, a bioactive compound from Pueraria lobata, improves glucose and lipid metabolism in type 2 diabetes (T2D) mice by restoring gut microbiota balance and promoting adipose tissue thermogenesis. Key mechanistic insights reveal modulation of the PI3K/AKT/PPARγ pathway, supporting new strategies for metabolic disease intervention.
USP42 Drives Breast Cancer Progression via JNK/p38 Apoptosis
2026-05-02
This study systematically demonstrates that the deubiquitinating enzyme USP42 promotes breast cancer progression by inhibiting JNK and p38-mediated apoptosis. The findings clarify a key oncogenic signaling mechanism and suggest USP42 as a promising therapeutic target for breast cancer intervention.
Iptacopan (LNP023): Applied Protocols for Complement Pathway
2026-05-02
Iptacopan (LNP023) enables precise, reversible inhibition of the alternative complement pathway, setting a new standard for functional and translational assays in complement activation research. This guide delivers actionable protocols, troubleshooting insights, and comparative context for maximizing data fidelity in both in vitro and in vivo models.
DiscoveryProbe Protease Inhibitor Library: Evidence and Work
2026-05-01
The DiscoveryProbe Protease Inhibitor Library enables high-throughput, reproducible protease inhibition studies. Its validated, diverse compound set and automation-ready format support cancer and infectious disease research. This article details biological rationale, mechanism, evidence, and integration best practices.
Clozapine N-oxide: Chemogenetic Precision for Anxiety Resear
2026-04-30
This thought-leadership article explores the mechanistic and translational power of Clozapine N-oxide (CNO) as a chemogenetic actuator, with a focus on its role in dissecting inhibitory circuits and stress-induced anxiety behaviors. Integrating new data on cholecystokinin-expressing interneurons in the basolateral amygdala, the piece guides translational researchers on protocol choices, experimental pitfalls, and future horizons for targeted neuromodulation in neuroscience.
Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding
2026-04-30
A recent study demonstrates that naturally occurring angiotensin peptide fragments, generated within the renin-angiotensin system, significantly enhance binding of the SARS-CoV-2 spike protein to the AXL receptor—a pathway distinct from ACE2. These findings reveal a new molecular interface linking cardiovascular signaling peptides and viral entry processes, underpinning the need for further mechanistic and translational research.
CDK4/6 and BET Inhibition Synergizes to Suppress EMT in PDAC
2026-04-29
Gu et al. (2025) reveal that combined inhibition of CDK4/6 and BET proteins synergistically suppresses pancreatic ductal adenocarcinoma (PDAC) growth and epithelial-to-mesenchymal transition (EMT) by modulating the GSK3β-mediated Wnt/β-catenin signaling pathway. These findings refine our understanding of compensatory signaling in PDAC and offer an evidence-based rationale for dual-targeted intervention strategies.
hiPSC-Derived Intestinal Organoids for Pharmacokinetics Rese
2026-04-29
This study establishes a direct 3D culture protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids suitable for in vitro pharmacokinetic studies. The approach yields organoids with robust self-renewal and differentiation capacity, enabling improved modeling of intestinal drug metabolism compared to conventional systems.
Omeprazole (A2845): Protocol Guidance for Gastric Acid Resea
2026-04-28
Omeprazole (A2845) is a potent H+,K+-ATPase inhibitor designed for research into gastric acid secretion and antiulcer mechanisms. This compound enables reproducible, high-specificity assays in gastric acid-related disease modeling but is unsuitable for diagnostic or clinical use. Researchers should adhere to solubility and storage constraints for optimal results.
4μ8C: Selective IRE1 RNase Inhibition for ER Stress Research
2026-04-28
4μ8C (7-hydroxy-4-methyl-2-oxochromene-8-carbaldehyde) enables precise dissection of the unfolded protein response by selectively targeting IRE1 RNase activity in cellular models of hypoxia and ER stress. Its unique specificity streamlines mechanistic studies of cancer, degeneration, and inflammation, offering researchers robust protocols and troubleshooting strategies for advanced ER stress modulation.
Carboplatin (SKU A2171): Precision DNA Synthesis Inhibition
2026-04-27
This article offers an evidence-based guide to leveraging Carboplatin (SKU A2171), a platinum-based DNA synthesis inhibitor, for robust cell viability and cytotoxicity assays in preclinical oncology research. Drawing on real laboratory scenarios and recent mechanistic literature, we address protocol optimization, data interpretation, and vendor selection—all grounded in practical workflow requirements and transparent sourcing.
Reliable Workflows with Angiotensin (1-7) (SKU A1041): Lab S
2026-04-27
This article delivers scenario-driven guidance for using Angiotensin (1-7) (SKU A1041) in cell viability and mechanistic assays, highlighting evidence-based solutions to common challenges in protocol optimization, data interpretation, and reagent selection. Researchers will find actionable parameters, peer-reviewed context, and practical vendor comparisons to enhance workflow reproducibility and scientific rigor.
461 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page